CN102481290A - 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 - Google Patents

用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 Download PDF

Info

Publication number
CN102481290A
CN102481290A CN2010800303038A CN201080030303A CN102481290A CN 102481290 A CN102481290 A CN 102481290A CN 2010800303038 A CN2010800303038 A CN 2010800303038A CN 201080030303 A CN201080030303 A CN 201080030303A CN 102481290 A CN102481290 A CN 102481290A
Authority
CN
China
Prior art keywords
berberine
rosacea
pharmaceutical composition
external use
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800303038A
Other languages
English (en)
Chinese (zh)
Inventor
洪舜郁
钟文宏
张子文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510859124.XA priority Critical patent/CN105534978A/zh
Publication of CN102481290A publication Critical patent/CN102481290A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010800303038A 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物 Pending CN102481290A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510859124.XA CN105534978A (zh) 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22172509P 2009-06-30 2009-06-30
US61/221,725 2009-06-30
PCT/CN2010/000983 WO2011000218A1 (en) 2009-06-30 2010-06-30 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510859124.XA Division CN105534978A (zh) 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物

Publications (1)

Publication Number Publication Date
CN102481290A true CN102481290A (zh) 2012-05-30

Family

ID=43410481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800303038A Pending CN102481290A (zh) 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物
CN201510859124.XA Pending CN105534978A (zh) 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510859124.XA Pending CN105534978A (zh) 2009-06-30 2010-06-30 用于治疗红斑痤疮或红脸相关皮肤病的含黄连素或其类似物的组合物

Country Status (16)

Country Link
US (1) US9486402B2 (enExample)
EP (1) EP2448577B1 (enExample)
JP (2) JP6159084B2 (enExample)
KR (3) KR20170010442A (enExample)
CN (2) CN102481290A (enExample)
AU (1) AU2010268647B2 (enExample)
BR (1) BRPI1012128A2 (enExample)
CA (1) CA2766834C (enExample)
ES (1) ES2600909T3 (enExample)
HK (1) HK1224206A1 (enExample)
IL (1) IL217264A (enExample)
MX (1) MX344787B (enExample)
NZ (1) NZ597645A (enExample)
PL (1) PL2448577T3 (enExample)
RU (2) RU2533458C2 (enExample)
WO (1) WO2011000218A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163280A (zh) * 2013-12-19 2016-11-23 安成生物科技股份有限公司 小檗碱制剂及其用途
CN107921284A (zh) * 2015-06-24 2018-04-17 安成生物科技股份有限公司 小檗碱制剂的治疗用途
CN110882246A (zh) * 2018-09-08 2020-03-17 西南大学 不同生物活性的黄连生物碱的提取方法及应用
TWI794200B (zh) * 2017-01-19 2023-03-01 安成生物科技股份有限公司 預防或治療免疫發炎性皮膚疾病的方法及醫藥組合物
CN116370469A (zh) * 2023-04-27 2023-07-04 常州大学 四氢小檗碱类化合物对trpv3的抑制应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3398448A1 (en) 2017-05-05 2018-11-07 Vall Garraf, S.L. Fattening additive for animal nutritional composition
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
GB2589729A (en) * 2018-04-18 2021-06-09 Forte Subsidiary Inc Compositions for the treatment of skin conditions
CN108329310A (zh) * 2018-05-07 2018-07-27 深圳市迪克曼科技开发有限公司 黄藤素的制备方法
GB2588721A (en) 2018-05-11 2021-05-05 Forte Subsidiary Inc Compositions for the treatment of skin conditions
JP2020045338A (ja) * 2018-09-12 2020-03-26 大正製薬株式会社 外用組成物
SG11202102204PA (en) 2018-09-25 2021-04-29 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
RU2697854C1 (ru) * 2019-05-14 2019-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ комбинированной наружной терапии эритематозно-папулезной розацеа
CN113440613A (zh) * 2020-03-26 2021-09-28 轶诺(浙江)药业有限公司 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
CN1923199A (zh) * 2005-08-29 2007-03-07 中国医学科学院皮肤病研究所 盐酸13－己基小檗碱和盐酸13－己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150920A (ja) * 1984-08-20 1986-03-13 Ichimaru Fuarukosu Kk 黄柏抽出エキス含有液の製造法
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
JP2001335485A (ja) * 2000-05-31 2001-12-04 Pola Chem Ind Inc メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
WO2004093876A2 (en) * 2003-04-03 2004-11-04 The Board Of Trustees Of The University Of Illinois Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
EP1591125A1 (de) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung enthaltend Extrakte aus Flechten und Johanniskraut
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
CN1923199A (zh) * 2005-08-29 2007-03-07 中国医学科学院皮肤病研究所 盐酸13－己基小檗碱和盐酸13－己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163280A (zh) * 2013-12-19 2016-11-23 安成生物科技股份有限公司 小檗碱制剂及其用途
CN107921284A (zh) * 2015-06-24 2018-04-17 安成生物科技股份有限公司 小檗碱制剂的治疗用途
TWI794200B (zh) * 2017-01-19 2023-03-01 安成生物科技股份有限公司 預防或治療免疫發炎性皮膚疾病的方法及醫藥組合物
CN110882246A (zh) * 2018-09-08 2020-03-17 西南大学 不同生物活性的黄连生物碱的提取方法及应用
CN116370469A (zh) * 2023-04-27 2023-07-04 常州大学 四氢小檗碱类化合物对trpv3的抑制应用

Also Published As

Publication number Publication date
ES2600909T3 (es) 2017-02-13
EP2448577A4 (en) 2012-12-26
US9486402B2 (en) 2016-11-08
JP6159084B2 (ja) 2017-07-05
PL2448577T3 (pl) 2017-02-28
RU2014136492A (ru) 2016-03-27
RU2533458C2 (ru) 2014-11-20
KR20170010442A (ko) 2017-01-31
KR20170116231A (ko) 2017-10-18
BRPI1012128A2 (pt) 2016-03-29
CA2766834A1 (en) 2011-01-06
KR101699572B1 (ko) 2017-01-24
EP2448577B1 (en) 2016-09-14
WO2011000218A1 (en) 2011-01-06
KR20120047240A (ko) 2012-05-11
CN105534978A (zh) 2016-05-04
RU2012102898A (ru) 2013-08-10
HK1224206A1 (zh) 2017-08-18
MX344787B (es) 2017-01-05
IL217264A0 (en) 2012-02-29
JP2012531448A (ja) 2012-12-10
JP2017082019A (ja) 2017-05-18
US20120165357A1 (en) 2012-06-28
AU2010268647B2 (en) 2015-01-15
MX2011014006A (es) 2012-06-12
EP2448577A1 (en) 2012-05-09
IL217264A (en) 2017-01-31
AU2010268647A1 (en) 2012-02-09
CA2766834C (en) 2017-04-25
RU2671492C2 (ru) 2018-11-01
NZ597645A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
AU2010268647B2 (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
Zhao et al. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis
Guo et al. Vanillin protects the blood–milk barrier and inhibits the inflammatory response in LPS-induced mastitis in mice
Makhija et al. Chemical chaperones mitigate experimental asthma by attenuating endoplasmic reticulum stress
Zhou et al. Phillygenin ameliorates nonalcoholic fatty liver disease via TFEB-mediated lysosome biogenesis and lipophagy
JP6310971B2 (ja) Ｈｉｖ関連の下痢を治療するための方法および組成物
Nguyen et al. Natural Compound Mixture, Containing Emodin, Genipin, Chlorogenic Acid, Cimigenoside, and Ginsenoside Rb1, Ameliorates Psoriasis‐Like Skin Lesions by Suppressing Inflammation and Proliferation in Keratinocytes
US11471501B2 (en) Pharmaceutical composition for use in the treatment of prostate pathologies
JP2016505561A (ja) Ｈｉｖ関連下痢を治療する方法および組成物
CN103458884A (zh) 用于治疗肾病的方法及组合物
JP6185575B2 (ja) 皮膚炎症性疾患の治療方法
WO2018175334A1 (en) Compositions and methods for skin treatments
EP3982909A1 (en) Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue
KR20210036369A (ko) 자외선으로부터 피부를 보호하기 위한 라이코펜 조성물 및 방법
CN114366732B (zh) 泰妙菌素在制备用于治疗银屑病的药物中的应用
KR102751617B1 (ko) 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
JP2024128926A (ja) 顔の皮膚状態の改善剤
Samsonov New Drugs Against Acne Vulgaris In The Light Of Paradigm Shift: From Bacteria to Inflammation Target
CN104394874A (zh) 用于治疗动脉硬化性血管病的方法和组合物
HK1187539A (en) Methods and compositions for treating kidney disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120530